P53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus

Annals of Surgical Oncology

Volumn 17, Issue 2, 2010, Pages 634-642

  Yamasaki, Makoto ^a   Miyata, Hiroshi ^a   Fujiwara, Yoshiyuki ^a   Takiguchi, Shuji ^a   Nakajima, Kiyokazu ^a   Nishida, Toshirou ^a   Yasuda, Takushi ^b   Matsuyama, Jin ^c   Mori, Masaki ^a   Doki, Yuichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Yao Municipal Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; PROTEIN P53; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CONTINUOUS INFUSION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUTANT; POLYMERASE CHAIN REACTION; PREDICTION; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SINGLE STRAND CONFORMATION POLYMORPHISM; STENT; TREATMENT RESPONSE; TUMOR BIOPSY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DOXORUBICIN; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77149145188     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0851-4     Document Type: Article

References (52)

1. BH Burmeister JW Denham M O'Brien, et al. 1995 Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study Int J Radiat Oncol Biol Phys 32 4 997 1006 1:STN:280:DyaK2Mzjt1Wjtw%3D%3D 7607974
2. JL Lee SI Park SB Kim, et al. 2004 A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma Ann Oncol 15 6 947 954 10.1093/annonc/mdh219 1:CAS:528:DC%2BD2MXks1KrsA%3D%3D 15151953 (Pubitemid 39004352)
3. DP Kelsen R Ginsberg TF Pajak, et al. 1998 Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer N Engl J Med 339 27 1979 1984 10.1056/NEJM199812313392704 1:STN:280:DyaK1M%2FnslCjsg%3D%3D 9869669 (Pubitemid 29024130)
4. V Gebski B Burmeister BM Smithers K Foo J Zalcberg J Simes 2007 Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis Lancet Oncol 8 3 226 234 10.1016/S1470-2045(07)70039- 6 1:CAS:528:DC%2BD2sXisVCqs78%3D 17329193 (Pubitemid 46291702)
5. JA Roth HI Pass MM Flanagan GM Graeber JC Rosenberg S Steinberg 1988 Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus J Thorac Cardiovasc Surg 96 2 242 248 1:STN:280:DyaL1c3oslCktQ%3D%3D 2456424
6. K Nygaard S Hagen HS Hansen, et al. 1992 Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer World J Surg 16 6 1104 1109 10.1007/BF02067069 1:STN:280:DyaK3s%2FovVyhsg%3D%3D 1455880 discussion 10
7. C Apinop P Puttisak N Preecha 1994 A prospective study of combined therapy in esophageal cancer Hepatogastroenterology 41 4 391 393 1:STN:280:DyaK2M%2FkvVWisQ%3D%3D 7959579
8. E Le Prise PL Etienne B Meunier, et al. 1994 A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus Cancer 73 7 1779 1784 10.1002/1097-0142(19940401)73:7<1779::AID-CNCR2820730702>3.0.CO;2-T 8137201
9. DP Kelsen KA Winter LL Gunderson, et al. 2007 Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer J Clin Oncol 25 24 3719 3725 10.1200/JCO.2006.10.4760 17704421 (Pubitemid 47372613)
10. T Maipang P Vasinanukorn C Petpichetchian, et al. 1994 Induction chemotherapy in the treatment of patients with carcinoma of the esophagus J Surg Oncol 56 3 191 197 10.1002/jso.2930560314 1:STN:280:DyaK2czgtV2ruw%3D%3D 7518020 (Pubitemid 24226640)
11. S Law M Fok S Chow KM Chu J Wong 1997 Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial J Thorac Cardiovasc Surg 114 2 210 217 10.1016/S0022-5223(97)70147-8 1:STN:280:DyaK2svhs1Krug%3D%3D 9270638 (Pubitemid 27364211)
12. RA Malthaner S Collin D Fenlon 2006 Preoperative chemotherapy for resectable thoracic esophageal cancer Cochrane Database Syst Rev. 3 CD001556 1:STN:280:DC%2BD28vivFamuw%3D%3D 16855972
13. JF Bosset M Gignoux JP Triboulet, et al. 1997 Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus N Engl J Med 337 3 161 167 10.1056/NEJM199707173370304 1:STN:280: DyaK2szkslaitA%3D%3D 9219702 (Pubitemid 27306287)
14. SG Urba MB Orringer A Turrisi M Iannettoni A Forastiere M Strawderman 2001 Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma J Clin Oncol 19 2 305 313 1:CAS:528:DC%2BD3MXhtVektrs%3D 11208820
15. Medical Research Council Oesophageal Cancer Working Party 2002 Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial Lancet 359 9319 1727 1733 10.1016/S0140-6736(02) 08651-8 (Pubitemid 34607086)
16. E Ancona A Ruol S Santi, et al. 2001 Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone Cancer 91 11 2165 2174 10.1002/1097-0142(20010601)91:11<2165::AID- CNCR1245>3.0.CO;2-H 1:STN:280:DC%2BD3MzhvFeitA%3D%3D 11391598 (Pubitemid 32476382)
17. M Yano K Takachi Y Doki, et al. 2006 Preoperative chemotherapy for clinically node-positive patients with squamous cell carcinoma of the esophagus Dis Esophagus 19 3 158 163 10.1111/j.1442-2050.2006.00558.x 1:STN:280: DC%2BD283ptlagtQ%3D%3D 16722992 (Pubitemid 43756662)
18. CC Harris 1996 Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies J Natl Cancer Inst 88 20 1442 1455 10.1093/jnci/88.20.1442 1:CAS:528:DyaK28XmsVSqs7Y%3D 8841019 (Pubitemid 26340046)
19. T Jacks RA Weinberg 1996 Cell-cycle control and its watchman Nature 381 6584 643 644 10.1038/381643a0 1:CAS:528:DyaK28Xjslahsb0%3D 8649505 (Pubitemid 26196558)
20. SW Lowe HE Ruley T Jacks DE Housman 1993 p53-dependent apoptosis modulates the cytotoxicity of anticancer agents Cell 74 6 957 967 10.1016/0092-8674(93)90719-7 1:CAS:528:DyaK3sXlvFGhtLk%3D 8402885 (Pubitemid 23289454)
21. J Sjostrom C Blomqvist P Heikkila, et al. 2000 Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer Clin Cancer Res 6 8 3103 3110 1:CAS:528:DC%2BD3cXmsVOmtr4%3D 10955790
22. F Bataille P Rummele W Dietmaier, et al. 2003 Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer Mol Pathol 56 5 286 292 10.1136/mp.56.5.286 1:CAS:528:DC%2BD3sXptVCht7g%3D 14514923 (Pubitemid 37243921)
23. D Kandioler-Eckersberger C Ludwig M Rudas, et al. 2000 TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients Clin Cancer Res 6 1 50 56 1:CAS:528:DC%2BD3cXhtVequ78%3D 10656431
24. D Kandioler-Eckersberger S Kappel M Mittlbock, et al. 1999 The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer J Thorac Cardiovasc Surg 117 4 744 750 10.1016/S0022-5223(99)70295-3 1:CAS:528:DyaK1MXisVGlu7Y%3D 10096970
25. L Licitra S Suardi P Bossi, et al. 2004 Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma J Clin Oncol 22 24 4901 4906 10.1200/JCO.2004.05. 071 1:CAS:528:DC%2BD2MXptVWktQ%3D%3D 15611505 (Pubitemid 46638614)
26. Nakashima S, Natsugoe S, Matsumoto M, Kijima F, Takebayashi Y, Okumura H, et al. Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma. Anticancer Res. 2000;20(3B):1933-7.
27. U Ribeiro Jr SD Finkelstein AV Safatle-Ribeiro, et al. 1998 p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma Cancer 83 1 7 18 10.1002/(SICI)1097-0142(19980701)83:1<7::AID- CNCR2>3.0.CO;2-R 1:CAS:528:DyaK1cXktlejsLc%3D 9655287 (Pubitemid 28299623)
28. K Kishi Y Doki H Miyata M Yano T Yasuda M Monden 2002 Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer Br J Surg 89 5 597 603 10.1046/j.1365-2168.2002.02057.x 1:STN:280: DC%2BD383jsFehtA%3D%3D 11972550 (Pubitemid 34415610)
29. H Shiozaki M Yano T Tsujinaka, et al. 2001 Lymph node metastasis along the recurrent nerve chain is an indication for cervical lymph node dissection in thoracic esophageal cancer Dis Esophagus 14 3-4 191 196 10.1046/j.1442-2050. 2001.00206.x 1:STN:280:DC%2BD387jtl2mtA%3D%3D 11869318 (Pubitemid 34170807)
30. S Yoshioka Y Fujiwara Y Sugita, et al. 2002 Real-time rapid reverse transcriptase-polymerase chain reaction for intraoperative diagnosis of lymph node micrometastasis: clinical application for cervical lymph node dissection in esophageal cancers Surgery 132 1 34 40 10.1067/msy.2002.125306 12110793 (Pubitemid 34787819)
31. H Miyata M Yano Y Doki, et al. 2006 A prospective trial for avoiding cervical lymph node dissection for thoracic esophageal cancers, based on intra-operative genetic diagnosis of micrometastasis in recurrent laryngeal nerve chain nodes J Surg Oncol 93 6 477 484 10.1002/jso.20453 16615150 (Pubitemid 44651271)
32. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437
33. N Urano Y Fujiwara Y Doki, et al. 2006 Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer Int J Oncol 28 2 375 381 1:CAS:528:DC%2BD28XhsFSgur4%3D 16391792
34. MC Hollstein RA Metcalf JA Welsh R Montesano CC Harris 1990 Frequent mutation of the p53 gene in human esophageal cancer Proc Natl Acad Sci U S A 87 24 9958 9961 10.1073/pnas.87.24.9958 1:CAS:528:DyaK3MXls1Ohuw%3D%3D 2263646
35. S Kobayashi Y Koide M Endo K Isono T Ochiai 1999 The p53 gene mutation is of prognostic value in esophageal squamous cell carcinoma patients in unified stages of curability Am J Surg 177 6 497 502 10.1016/S0002-9610(99)00085-9 1:CAS:528:DC%2BD3cXpt12mtg%3D%3D 10414702 (Pubitemid 29331482)
36. A Eastman 1990 Activation of programmed cell death by anticancer agents: cisplatin as a model system Cancer Cells 2 8-9 275 280 1:CAS:528: DyaK3MXnsVGnsA%3D%3D 2223389
37. HJ Lenz K Hayashi D Salonga, et al. 1998 p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival Clin Cancer Res 4 5 1243 1250 1:CAS:528:DyaK1cXjt1yiu70%3D 9607583
38. A Cabelguenne H Blons I de Waziers, et al. 2000 p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series J Clin Oncol 18 7 1465 1473 1:CAS:528: DC%2BD3cXivVeisrc%3D 10735894
39. P Fouret S Temam F Charlotte J Lacau-St-Guily 2002 Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck Br J Cancer 87 12 1390 1395 10.1038/sj.bjc. 6600648 1:CAS:528:DC%2BD38XovFKrs7Y%3D 12454767 (Pubitemid 36044313)
40. S Temam A Flahault S Perie, et al. 2000 p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck J Clin Oncol 18 2 385 394 1:CAS:528:DC%2BD3cXps1Oqtw%3D%3D 10637254
41. K Muro A Ohtsu N Boku, et al. 1996 Association of p53 protein expression with responses and survival of patients with locally advanced esophageal carcinoma treated with chemoradiotherapy Jpn J Clin Oncol 26 2 65 69 1:STN:280:DyaK287osFajsw%3D%3D 8609696
42. KY Lam S Law LT Ma SK Ong J Wong 1997 Pre-operative chemotherapy for squamous cell carcinoma of the oesophagus: do histological assessment and p53 overexpression predict chemo-responsiveness? Eur J Cancer 33 8 1221 1225 10.1016/S0959-8049(97)00094-4 1:STN:280:DyaK2svks12qtw%3D%3D 9301446 (Pubitemid 27359639)
43. Y Shimada G Watanabe S Yamasaki, et al. 2000 Histological response of cisplatin predicts patients' survival in oesophageal cancer and p53 protein accumulation in pretreatment biopsy is associated with cisplatin sensitivity Eur J Cancer 36 8 987 993 10.1016/S0959-8049(00)00049-6 1:CAS:528: DC%2BD3cXjsVCqsLo%3D 10885602 (Pubitemid 30316423)
44. CJ Fisher CE Gillett B Vojtesek DM Barnes RR Millis 1994 Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation Br J Cancer 69 1 26 31 1:STN:280:DyaK2c7hsVenuw%3D%3D 7506924
45. D Wynford-Thomas 1992 P53 in tumour pathology: can we trust immunocytochemistry? J Pathol 166 4 329 330 10.1002/path.1711660402 1:STN:280:DyaK38zovFSqtA%3D%3D 1517889
46. CA Finlay PW Hinds TH Tan D Eliyahu M Oren AJ Levine 1988 Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life Mol Cell Biol. 8 531 539 1:CAS:528:DyaL1cXht12nsbg%3D 2832726
47. SP Hussain CC Harris 1998 Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes Cancer Res. 58 4023 4037 1:CAS:528:DyaK1cXmtlClu7g%3D 9751603
48. Y Haupt R Maya A Kazaz M Oren 1997 Mdm2 promotes the rapid degradation of p53 Nature. 387 296 299 10.1038/387296a0 1:CAS:528:DyaK2sXjtlSgtL8%3D 9153395 (Pubitemid 27220766)
49. SM Bodner JD Minna SM Jensen, et al. 1992 Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation Oncogene. 7 743 749 1:CAS:528:DyaK38XisFehs7w%3D 1565469
50. PM O'Connor J Jackman I Bae, et al. 1997 Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents Cancer Res. 57 4285 4300 9331090
51. H Matsubara M Kimura M Sugaya, et al. 1999 Expression of wild-type p53 gene confers increased sensitivity to radiation and chemotherapeutic agents in human esophageal carcinoma cells Int J Oncol 14 6 1081 1085 1:CAS:528: DyaK1MXjvVOmsro%3D 10339661
52. H Shimada T Shimizu T Ochiai, et al. 2001 Preclinical study of p53 gene therapy for esopahgeal carcer Surgery Today. 31 597 604 10.1007/s005950170093 1:CAS:528:DC%2BD3MXmslSitb8%3D 11495154 (Pubitemid 32695785)